77 related articles for article (PubMed ID: 16541608)
1. P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors.
Kolomecki K; Maciaszczyk P; Stepien H; Stepien T; Kuzdak K; Ulanska J
Bratisl Lek Listy; 2005; 106(10):297-300. PubMed ID: 16541608
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
Kołomecki K; Maciaszczyk P; Stepień H; Cywiński J; Cielecka J; Stepień T; Kuzdak K
Endokrynol Pol; 2006; 57(4):320-5. PubMed ID: 17006831
[TBL] [Abstract][Full Text] [Related]
3. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients.
Kosacka M; Porębska I; Korzeniewska A; Rubinsztajn R; Grabicki M; Jankowska R; Batura-Gabryel H; Chazan R
Pneumonol Alergol Pol; 2016; 84(1):11-5. PubMed ID: 26687668
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
8. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma.
Mezei G; Lévay M; Sepler Z; Héninger E; Kozma GT; Cserháti E
Pediatr Allergy Immunol; 2006 Sep; 17(6):444-9. PubMed ID: 16925690
[TBL] [Abstract][Full Text] [Related]
9. Circulating soluble Fas ligand in patients with gastric carcinoma.
Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
[TBL] [Abstract][Full Text] [Related]
10. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-related proteins (Fas, Fas ligand, bcl-2 and p53) in different types of human breast tumors.
Ben-Hur H; Mordechay E; Halperin R; Gurevich P; Zandbank J; Herper M; Zusman I
Oncol Rep; 2002; 9(5):977-80. PubMed ID: 12168058
[TBL] [Abstract][Full Text] [Related]
12. p53 antibody: is it an indicator of dedifferentiated thyroid cancer?
Hasbek Z; Turgut B; Erselcan T
Ann Nucl Med; 2014 Jan; 28(1):42-6. PubMed ID: 24234516
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
14. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
Hedayati M; Kołomecki K; Pasieka Z; Korzeniowska M; Kuzdak K
Endokrynol Pol; 2005; 56(3):252-8. PubMed ID: 16350718
[TBL] [Abstract][Full Text] [Related]
17. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome.
Liu JM; Zhu Y; Xu ZW; Ouyang WM; Wang JP; Liu XS; Cao YX; Li Q; Fang L; Zhuang R; Yang AG; Jin BQ
Clin Immunol; 2006 Jun; 119(3):245-51. PubMed ID: 16616877
[TBL] [Abstract][Full Text] [Related]
18. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
19. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
[TBL] [Abstract][Full Text] [Related]
20. HBV-DNA and sFas, sFasL concentrations in serum of healthy HBsAg carriers.
Lapiński TW; Kowalczuk O; Prokopowicz D; Chyczewski L; Jaroszewicz J
Rocz Akad Med Bialymst; 2005; 50():179-82. PubMed ID: 16358961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
